Unit
- Phase I trials: these first-in-human studies focus on safety, dosage range, and pharmacokinetics, typically enrolling small groups of healthy volunteers or, in oncology, patients with the target condition, with coordinators tracking dose escalation cohorts closely.
- Phase II trials: these studies expand enrollment to evaluate preliminary efficacy and further characterize safety in the target patient population, requiring coordinators to manage larger participant rosters and more complex visit schedules than Phase I.
- Phase III trials: these large-scale, often multi-site and multinational studies confirm efficacy, monitor adverse reactions, and compare the investigational product to standard treatments, demanding rigorous coordination across many sites and countries.
- Phase IV trials: also called post-marketing surveillance, these occur after regulatory approval to monitor long-term safety and effectiveness in the general population, often involving registries and observational data collection.
- Sponsor role: the sponsor, whether a pharmaceutical company, academic institution, or government agency, initiates and funds the trial, sets the protocol, and holds ultimate responsibility for regulatory submissions and overall study conduct.
- Contract research organizations: CROs are often hired by sponsors to manage day-to-day trial operations, including site selection, monitoring, and data management, and coordinators frequently interact with CRO monitors rather than sponsor staff directly.
- Investigational new drug applications: before human testing begins in the United States, sponsors must file an application with the regulatory authority demonstrating preclinical safety data, and coordinators should understand this document exists as the foundation authorizing the study.
- Protocol as the governing document: every trial phase operates under a detailed protocol specifying eligibility criteria, procedures, visit schedules, and endpoints, and coordinators must treat this document as the non-negotiable blueprint for all site activities.
- Adaptive trial designs: some modern trials incorporate adaptive elements allowing modification of sample size or treatment arms based on interim data, requiring coordinators to stay alert to protocol amendments that may arrive mid-study.
- Global regulatory variation: phase definitions and requirements can differ slightly across regulatory jurisdictions, so coordinators working on international trials should recognize that harmonization efforts like ICH guidelines exist but local nuances still apply.
Scope of Practice
Role: Clinical Trial Coordinator in Study Phase Support
Within scope:
- Tracking which phase a study is in and communicating phase-specific visit requirements to participants
- Maintaining accurate records of enrollment numbers relative to phase-specific targets
- Coordinating logistics for dose-escalation cohort scheduling as directed by the protocol
- Relaying phase-related protocol amendments to the site team and updating study binders
Outside scope:
- Determining whether a participant should progress within a dose-escalation cohort
- Making clinical judgments about phase transition readiness
- Interpreting pharmacokinetic data to advise on dosing decisions
- Authorizing protocol amendments without sponsor and IRB approval
Quick Revision
- Clinical trials progress through four main phases, each with distinct goals from safety to post-market surveillance.
- Sponsors hold ultimate responsibility while CROs often manage daily operations that coordinators interact with directly.
- The protocol document governs every aspect of study conduct and must be followed precisely.
- Coordinators support phase-specific logistics but do not make clinical or regulatory decisions.